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Abstract
Background:  To investigate the efficacy of posterior subtenon methylprednisolone acetate
injection in treatment of refractory diffuse clinically significant diabetic macular edema (CSME).
Methods: In a prospective, nonrandomized, interventional case series, 52 eyes were diagnosed
with CSME and treated with at least two sessions of laser photocoagulation according to Early
Treatment Diabetic Retinopathy Study guidelines. At least 3 months after laser therapy, eyes with
a residual central macular thickness were offered posterior subtenon injection of 40 mg
methylprednisolone acetate. Main outcome measures were visual acuity, macular thickness and
intraocular pressure. Potential complications were monitored, including intraocular pressure
response, cataract progression and scleral perforation.
Results: Mean baseline visual acuity (in logMAR) improved significantly (p = 0.003) from 0.8 ± 0.36
to 0.6 ± 0.41 at 3 months. Mean foveal thickness decreased from 388 ± 78 μm at baseline to 231
± 40 μm after 3 months (p  < 0.0001). Visual acuity improvement in eyes with CSME with
extrafoveal hard exudates was significant (p = 0.0001), but not significant in eyes with CSME with
subfoveal hard exudates (p = 0.32). Intraocular pressure increased from 14.7 ± 2.0 mmHg (range,
12–18 mmHg) to a maximum value of 15.9 ± 2.1 mmHg (range, 12–20 mmHg) during the follow-
up period. Complications in two eyes developed focal conjunctival necrosis at the site of injection.
Conclusion: Posterior subtenon methylprednisolone acetate may improve early visual outcome
in diffuse diabetic macular edema that fails to respond to conventional laser photocoagulation.
Visual acuity improvement in eyes with CSME with extrafoveal hard exudates was significant; and
this improvement is depends on location of hard exudates. Further study is needed to assess the
long-term efficacy, safety, and retreatment.
Background
Diabetic retinopathy is the major cause of blindness in the
United States in patients younger than 50 years of age, and
macular edema is the leading cause of visual impairment
in diabetic patients [1]. As might be expected, the preva-
lence of macular edema is directly related to the overall
severity of the retinopathy and instruction, ranging from
3% among eyes with mild non proliferative diabetic retin-
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opathy (NPDR) to 38% among eyes with moderate to
severe NPDR and 71% among eyes with proliferative dia-
betic retinopathy [2].
The Early Treatment Diabetic Retinopathy Study (EDTRS)
showed that laser photocoagulation has significant bene-
fit for the treatment of localized clinically significant mac-
ular edema [3]. However, some clinical features are
associated with poorer visual acuity outcomes after pho-
tocoagulation: diffuse macular edema with center
involved, diffuse fluorescein leakage, macular ischemia
(extensive perifoveal capillary nonperfusion), hard exu-
dates deposits in the foveola, marked cystoid macular
edema [4]. Diffuse and prolonged edema may fail to
respond to laser photocoagulation or may returns after
initial improvement [5-7]. Substantial subgroups of
patients with refractory macular edema prompted interest
in other treatment modalities, including pars plana vitrec-
tomy [8], medical therapy with protein kinase C inhibi-
tors [9], intravitreal injection of corticosteroids [9-11] or a
sustained release intravitreal corticosteroid implant [9].
Subtenon and retrobulbar injections of long acting corti-
costeroids have been used for treatment of cystoid macu-
lar edema (CME) secondary to uveitis [12,13] or
intraocular surgeries [14]. Some studies showed accepta-
ble results for intravitreal injection of triamcinolone ace-
tonide, a corticosteroid suspension, in the treatment of
uveitis and diabetic macular edema [9-11], [15,16]. Intra-
vitreal injection has its potential complications and needs
special setting to be done; also drug localization to the
macula is important in obtaining maximum therapeutic
effect [17].
Recent studies showed that trans-tenon's retrobulbar infu-
sion and posterior subtenon injection of the corticoster-
oids are effective in treating posterior inflammation and
macular edema associated with uveitis [12,18] and
intraocular surgeries [19]. Because of localization of drug
in the macula, posterior subtenon and retrobulbar injec-
tions are equally effective in the treatment of CME [17].
The main advantage of posterior subtenon steroid injec-
tion is a prolonged effect due to a maximal local concen-
tration of the drug that causes minimal systemic side
effects [20]. The aim of the present study is to assess the
effects of subtenon injection of methylprednisolone ace-
tate in the management of persistent and refractory clini-
cally significant diabetic macular edema.
Methods
In a prospective, nonrandomized, interventional case
series 52 eyes of 52 diabetic individuals were diagnosed
with clinically significant macular edema (CSME) accord-
ing to EDTRS criteria. Approval for the study was obtained
from the ethical committee of Tabriz University of Medi-
cal Sciences which is in compliance with the Helsinki Dec-
laration. All patients received a thorough explanation of
the study design and aims, and were provided with writ-
ten informed consent. All patients were evaluated and
treated by retina specialist. Inclusion criteria were patients
with type II diabetes, persistent diffuse CSME 3 months
after at least 2 sessions of macular laser photocoagulation,
visual acuity loss, and leakage shown by fluorescein angi-
ography (Imagenet 2000, Topcon TRC50IX, Topcon
Corp, Japan). Eyes with history of glaucoma, cataract
extraction, or other intraocular surgery were excluded
from the study. Eyes with an epiretinal membrane, poste-
rior hyaloid traction, ischemic maculopathy, and diabetic
papillopathy were also excluded. The risks and benefits of
the procedure were discussed with each patient before
injection, and all patients provided written informed con-
sent. Baseline parameters were documented including
best corrected visual acuity, central macular thickness,
intraocular pressure (IOP) and lenticular status. The best-
corrected visual acuity was determined from the Early
Treatment Diabetic Retinopathy Study (EDTRS) chart and
calculated as logarithm of minimal angle of resolution
(logMAR). Central macular thickness was measured by
optical coherence tomography (OCT2; Zeiss-Humphrey
inc., Dublin, Ca). Optical coherence tomography (OCT)
was performed by acquiring six radial scans, 6 mm long,
centered in the fovea, and then analyzed with retinal map
protocol. Intraocular pressure was measured by applana-
tion tonometer. Systemic condition of the patients were
under control (blood glucose, blood pressure, and general
condition), and they were receiving oral hypoglycemic
agents or insulin for glycemic control.
All patients underwent posterior subtenon capsule injec-
tion of methylprednisolone acetate. Topical tetracaine
was applied to the ocular surface. A cotton-tipped applica-
tor soaked in tetracaine was then placed over the supero-
temporal quadrant for 2 minutes as the patient looked
inferonasally. The methyl prednisolone acetate suspen-
sion was then shaken and 1 cc (40 mg) was drawn into a
tuberculin syringe using a 25-gauge, 0.5-inch long needle.
The upper eyelid was lifted, and at the patient looked infe-
ronasally, the 25-gauge needle was used to penetrate the
posterior subtenon space. Before injection of the methyl
prednisolone acetate, the needle was moved from side to
side to check that the sclera was not engaged in the needle
tip. A 40 mg injection of methyl prednisolone was then
injected in the posterior subtenon space.
Location of hard exudates, detected by slit-lamp examina-
tion with a 78-diopter indirect lens, fundus photography
and fluorescein angiography; and all of the eyes divided
into two groups. Group 1 including of 30 eyes having
refractory diffuse CSME with extrafoveal hard exudates;
and group 2 including of 22 eyes having refractory diffuseBMC Ophthalmology 2006, 6:15 http://www.biomedcentral.com/1471-2415/6/15
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CSME with subfoveal hard exudates. Response to treat-
ment was monitored by snellen visual acuity and OCT.
IOP was recorded at every visit. Potential corticosteroid-
induced and injection-related complications were also
observed. Patients were observed 1 week, 1 and 3 months
after injection.
An ANOVA test was used to compare the Values before
and after treatment. Any differences showing a p-value of
less than or equal to 0.05 were considered to be statisti-
cally significant.
Results
The study included 52 eyes of 52 patients. Mean age ± SD
of the patients was 55 ± 7.6 years (median, 55 years;
range, 40 to 68 years). There were 25 males (48%) and 27
females (52%). There was no statistically significant dif-
ference in age and gender distribution of the patients. All
patients were in the stage of non proliferative diabetic
retinopathy (NPDR) and had at least two sessions of
MPC. Mean follow-up time ± SD was 3.6 ± 0.9 months
(median, 3 months; range 3–5 months). The mean log-
MAR visual acuity significantly improved from 0.8 ± 0.36
at baseline to 0.6 ± 0.42 at 1 week, 0.6 ± 0.43 at 1 month,
and 0.6 ± 0.41 at 3 months (Table 1). The mean foveal
thickness decreased from 388 ± 78 μm at baseline to 264
± 61 μm at 1 week, 230 ± 39 μm at 1 month, and 231 ± 40
μm at 3 months [Table 1].
Thirty eyes had CSME with extrafoveal hard exudates, and
22 eyes had CSME with subfoveal hard exudates. In eyes
with CSME with extrafoveal hard exudates, visual acuity
improvement was significant in follow-up interval (p <
0.0001); although was not significant in eyes with CSME
with subfoveal hard exudates (p = 0.32); Evaluation of vis-
ual acuity and retinal thickness in two groups was
explored. There were statistically significant differences
between baseline logMAR visual acuity and follow-up
intervals in eyes with CSME with extrafoveal hard exu-
dates (p < 0001), although in eyes with CSME with Sub-
foveal hard exudates were not statistically significant (p =
0.32); moreover macular thickness in two groups signifi-
cantly decreased during the follow-up period (p < 0.0001,
vs. p < 0.0001 respectively) [Table 2].
The mean baseline IOP was 14.7 ± 2.0 mmHg (range 12–
18 mmHg), and at 1 week, 1 month, and 3 months after
injection were 15.9 ± 2.1 mmHg (range 12–20), 15.7 ±
2.4 mmHg (range 12–20), and 15.3 ± 2.3 mmHg (range
12–18) respectively [Table 1].
In our study there were not any significant complications
such as ocular hypertension (IOP>21), globe rupture, or
cataract formation. Two patients developed focal conjunc-
tival injection and necrosis over the injection site that was
treated with antibiotic drops.
Discussion
Macular edema is the most frequent cause of visual
impairment in patients with NPDR [21]. Vascular perme-
ability, resulting in the leakage of fluid and plasma con-
stituents, such as lipoproteins into the retina, leads to
thickening of the retina [22]. When thickening involves or
threatens the center of the fovea, there is a higher risk of
visual loss. The EDTRS investigators classified macular
edema by its severity. It was defined as clinically signifi-
cant macular edema (CSME), if any of the following fea-
tures were present: thickening of the retina at or within
500 microns of the center of the macula, hard exudates at
or within 500 microns of the center of the macula, if asso-
ciated with thickening of the adjacent retina (not residual
hard exudates remaining after the disappearance of retinal
thickening), or a zone or zones of retinal thickening 1 disc
area or larger, and ultimately any part of which in 1 disc
diameter of the center of the macula [3]. Site of hard exu-
dates is one of the important factors for visual prognosis
after resolution of macular edema being either subfoveal
or extrafoveal.
Corticosteroids have been used of their ability to inhibit
the prostaglandin synthesis [10], and down regulate pro-
duction of vascular endothelial growth factor (VEGF). Sta-
bilization of blood retinal barrier (BRB) introduces a
rationale for corticosteroid treatment of diabetic macular
Table 1: Results of posterior subtenon methylprednisolone acetate injection for refractory diabetic macular edema.
Mean ± SD
Before injection After injection P-Value*
1 week 1 month 3 months
VA (logMAR) 0.8 ± 0.36 0.6 ± 0.42 0.6 ± 0.43 0.6 ± 0.41 0.003
CMT (μm) 388 ± 78 264 ± 61 230 ± 39 231 ± 40 0.0001
IOP (mmHg) 14.7 ± 2.0 15.9 ± 2.1 15.7 ± 2.4 15.3 ± 2.3 0.043
CMT = Central macular thickness; IOP = intraocular pressure; logMAR = logarithm of minimal angle of resolution; VA = visual acuity; *p < 0.05 is 
statistically significantBMC Ophthalmology 2006, 6:15 http://www.biomedcentral.com/1471-2415/6/15
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edema. Several studies showed the efficacy of intravitreal
injection of corticosteroids in the management of diabetic
macular edema [9-11]. Intravitreal injection is associated
with rapid drug delivery to action site with maximal bioa-
vailability, but has its complications. Recently trans-
tenon's retrobulbar infusion and sub-tenon's injection of
corticosteroids has been shown to be effective in the treat-
ment of cystoid macular edema in patients with uveitis
[12,15]. Subtenon injection of steroids in the treatment of
uveitis was first reported in 1998 by Tanner et al [15]. It is
a standard drug delivery method (with maximum concen-
tration of drug in macula), which is used for treatment of
chronic uveitis of posterior segment [13].
In retrospective, interventional case series, Chieh et al [23]
treated 210 eyes with 1 or 4 mg of intravitreal triamci-
nolone acetonide for treatment of diffuse diabetic macu-
lar edema. They found a mean improvement in visual
acuity from a median of 20/200 (mean logMAR, 0.92) at
baseline to 20/80 (mean logMAR, 0.82) at 6 months.
Mean intraocular pressure ± SD increased from 15.4 ± 3.4
mmHg to a maximal value of 20.4 ± 6.2 mmHg during the
follow-up period. There were many complications,
including culture-negative sterile endophthalmitis in six
cases and cataract extraction in five eyes.
In prospective comparative, interventional case series,
Jonas et al [11,24] studied 26 eyes injected with 25 mg of
intravitreal triamcinolone acetonide for the treatment of
diffuse diabetic macular edema. They showed that mean
visual acuity ± SD improved significantly (p < 0.001) from
0.12 ± 0.08 at baseline to a maximum of 0.19 ± 0.14 dur-
ing follow-up. Seventeen (81%) of 21 eyes with a follow-
up of 1 month had improved visual acuity. Visual acuity
did not change significantly in their control group. IOP
also increased significantly (p < 0.001) and decreased sig-
nificantly (p = 0.03) at the 5-month follow-up.
The main outcome measures of our study were best cor-
rected visual acuity (by logMAR) and macular thickness
(using OCT). Our results showed that, eyes had significant
visual acuity improvement when compared with baseline
as calculated by logMAR (p = 0.003), and also significant
visual acuity improvement in eyes having CSME with
extrafoveal hard exudates (p = 0.0001) but not significant
in eyes having CSME with Subfoveal hard exudates (p =
0.32). In all eyes our results indicate that macular thick-
ness significantly decreased between baseline and follow-
up interval (p = 0.0001), and also significantly decreased
in patients with CSME with extrafoveal and Subfoveal
hard exudates (p = 0.0001 and, p = 0.0001) respectively
[Table 2].
Ocular hypertension was not reported in this study. None
of our patients had ocular complications of steroids,
including development of cataract and glaucoma, pro-
longed healing of abrasions and epithelial defects [13].
Hemorrhage, globe perforation or perforation and
extraocular muscle necrosis which are potential complica-
tions of injection itself was not reported in our study. In
two patients developed focal conjunctival necrosis at the
site of injection that was cured after 7–10 days of follow
up with topical antibiotic.
Posterior subtenon methylprednisolone acetate may
improve diabetic macular edema, but visual acuity
improvement may depend on location of hard exudates.
According to the results obtained, in addition to those fac-
tors excluded in the subject selection, it is important in the
treatment of diabetic patients having CSME with hard
exudates; the exact location of the hard exudates should
be considered carefully.
Conclusion
This method is associated with low potential complica-
tions related to intravitreal injections. However, long-
Table 2: Results of posterior subtenon methylprednisolone acetate injection for refractory diabetic macular edema in two different 
groups.
Mean ± SD
Before injection After injection P-Value*
1 week 1 month 3 months
Group 1(n = 30)
VA (logMAR) 0.6 ± 0.27 0.3 ± 0.20 0.3 ± 0.21 0.3 ± 0.22 0.0001
CMT (μm) 367 ± 65 248 ± 44 222 ± 35 226 ± 40 0.0001
Group 2(n = 22)
VA (logMAR) 1.1 ± 0.27 1.0 ± 0.27 1.0 ± 0.25 1.0 ± 0.25 0.32
CMT (μm) 417 ± 86 286 ± 76 241 ± 43 238 ± 39 0.0001
CMT = central macular thickness; Group 1 = eyes having refractory diffuse CSME with extrafoveal hard exudates; Group 2 = eyes having refractory 
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term effects of posterior subtenon treatment are not clear.
We believe further studies using a larger population with
control will add valuable information to our results.
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